2022
Patient-Level Disease Burden as a Predictor of In-Field Failures in Patients Undergoing Bridging Radiotherapy for CD19-Directed Chimeric Antigen Receptor (CAR) T-Cell Therapy for Recurrent/Refractory Large B-Cell Lymphomas
Figura N, Sim A, Chavez J, Shah B, Khimani F, Lazaryan A, Davila M, Bachmeier C, Nishihori T, Liu H, Christopherson K, Kim S, Locke F, Jain M, Robinson T. Patient-Level Disease Burden as a Predictor of In-Field Failures in Patients Undergoing Bridging Radiotherapy for CD19-Directed Chimeric Antigen Receptor (CAR) T-Cell Therapy for Recurrent/Refractory Large B-Cell Lymphomas. International Journal Of Radiation Oncology • Biology • Physics 2022, 114: s85. DOI: 10.1016/j.ijrobp.2022.07.491.Peer-Reviewed Original ResearchMedian metabolic tumor volumeT-cell therapyRefractory large B-cell lymphomaCAR T-cell therapyLarge B-cell lymphomaBRT patientsDisease burdenTotal disease burdenB-cell lymphomaField progressionRadiation therapyLocal controlClinical outcomesExact testChimeric antigen receptor T-cell therapyCAR T-cell infusionDistant-only failureDurable local controlLocal-only failureWorse disease burdenFuture prospective trialsT-cell infusionHigh-risk patientsKaplan-Meier methodLow disease burdenUpfront Treatment With Osimertinib vs. Osimertinib and Radiotherapy for Patients With EGFR-Positive Non-Small Cell Lung Cancer Brain Metastases
Dohm A, Tang J, Mills M, Perez B, Robinson T, Creelan B, Yu H, Oliver D, Ahmed K. Upfront Treatment With Osimertinib vs. Osimertinib and Radiotherapy for Patients With EGFR-Positive Non-Small Cell Lung Cancer Brain Metastases. International Journal Of Radiation Oncology • Biology • Physics 2022, 112: e14. DOI: 10.1016/j.ijrobp.2021.10.186.Peer-Reviewed Original ResearchDistant intracranial controlEGFR-positive NSCLCBrain metastasesRadiation therapyBM diagnosisOverall survivalLocal controlMultivariate analysisSingle-institution retrospective analysisGeneration tyrosine kinase inhibitorsCentral nervous system penetrationUpfront radiation therapyKaplan-Meier methodProportional hazards modelTyrosine kinase inhibitorsMATERIAL/METHODSIntracranial radiation therapyIntracranial controlUpfront treatmentDS-GPAClinical outcomesResults MedianRetrospective analysisTreatment groupsHazards model
2021
Clinical Outcomes of Non-Small Cell Lung Cancer Brain Metastases Treated With Stereotactic Radiosurgery and Immune Checkpoint Inhibitors, EGFR Tyrosine Kinase Inhibitors, Chemotherapy and Immune Checkpoint Inhibitors, or Chemotherapy Alone
Dohm A, Tang J, Mills M, Perez B, Robinson T, Creelan B, Gray J, Etame A, Vogelbaum M, Forsyth P, Yu H, Oliver D, Ahmed K. Clinical Outcomes of Non-Small Cell Lung Cancer Brain Metastases Treated With Stereotactic Radiosurgery and Immune Checkpoint Inhibitors, EGFR Tyrosine Kinase Inhibitors, Chemotherapy and Immune Checkpoint Inhibitors, or Chemotherapy Alone. International Journal Of Radiation Oncology • Biology • Physics 2021, 111: e567. DOI: 10.1016/j.ijrobp.2021.07.1531.Peer-Reviewed Original ResearchEpidermal growth factor receptor tyrosine kinase inhibitorsImmune checkpoint inhibitorsDistant intracranial controlNon-small cell lung cancer brain metastasesCell lung cancer brain metastasesLung cancer brain metastasesTiming of SRSChemotherapy-alone groupNSCLC BM patientsNSCLC brain metastasesBrain metastasesCancer brain metastasesSystemic therapyRadiation necrosisStereotactic radiosurgeryCheckpoint inhibitorsOverall survivalTreatment groupsLocal controlMultivariate analysisBM patientsAlone groupClinical outcomesConventional chemotherapyGrowth factor receptor tyrosine kinase inhibitors
2020
RADT-02. CLINICAL OUTCOMES OF BREAST BRAIN METASTASES BY SUBTYPE FOLLOWING LINAC BASED STEREOTACTIC RADIATION
Thawani C, Mills M, Figura N, Sarangkasiri S, Washington I, Robinson T, Diaz R, Etame A, Vogelbaum M, Yu H, Ahmed K. RADT-02. CLINICAL OUTCOMES OF BREAST BRAIN METASTASES BY SUBTYPE FOLLOWING LINAC BASED STEREOTACTIC RADIATION. Neuro-Oncology 2020, 22: ii181-ii182. PMCID: PMC7651564, DOI: 10.1093/neuonc/noaa215.757.Peer-Reviewed Original ResearchBreast cancer subtypesBreast cancer brain metastasesBrain metastasis diagnosisCancer brain metastasesBrain metastasesStereotactic radiationOverall survivalClinical outcomesCancer subtypesHR-/HER2TN patientsMetastasis diagnosisHormone receptorsBreast cancer patientsBrain metastasis controlBreast brain metastasesOS ratesClinical chartsInstitutional seriesMedian ageSystemic metastasesInstitutional registryCancer patientsRadiologic examinationDisease progressionClinical Outcomes of Breast Cancer Brain Metastases Treated with Stereotactic Radiation and Capecitabine
Mills M, Naz A, Thawani C, Walker C, Figura N, Forsyth P, Etame A, Liu J, Vogelbaum M, Yu M, Robinson T, Soliman H, Han H, Ahmed K. Clinical Outcomes of Breast Cancer Brain Metastases Treated with Stereotactic Radiation and Capecitabine. International Journal Of Radiation Oncology • Biology • Physics 2020, 108: e685-e686. DOI: 10.1016/j.ijrobp.2020.07.2040.Peer-Reviewed Original ResearchClinical Outcomes of Breast Cancer Patients with HER2-positive Brain Metastases Treated with Stereotactic Radiation and Trastuzumab Emtansine
Mills M, Walker C, Thawani C, Naz A, Figura N, Yu M, Robinson T, Etame A, Liu J, Vogelbaum M, Forsyth P, Soliman H, Han H, Ahmed K. Clinical Outcomes of Breast Cancer Patients with HER2-positive Brain Metastases Treated with Stereotactic Radiation and Trastuzumab Emtansine. International Journal Of Radiation Oncology • Biology • Physics 2020, 108: e679-e680. DOI: 10.1016/j.ijrobp.2020.07.2026.Peer-Reviewed Original ResearchClinical Outcomes of Breast Brain Metastases by Subtype following LINAC Based Stereotactic Radiation
Mills M, Thawani C, Figura N, Sarangkasiri S, Washington I, Robinson T, Diaz R, Etame A, Vogelbaum M, Yu H, Ahmed K. Clinical Outcomes of Breast Brain Metastases by Subtype following LINAC Based Stereotactic Radiation. International Journal Of Radiation Oncology • Biology • Physics 2020, 108: e18-e19. DOI: 10.1016/j.ijrobp.2020.02.508.Peer-Reviewed Original Research
2019
CMET-17. RENAL CELL CARCINOMA BRAIN METASTASES TREATED WITH STEREOTACTIC RADIATION THERAPY AND NIVOLUMAB DOES NOT ALTER LESIONAL OR CLINICAL OUTCOMES
Mohammadi H, Tolpin A, Figura N, Peacock J, Oliver D, Sim A, Palm R, Ahmed K, Liu J, Tran N, Etame A, Vogelbaum M, Robinson T, Yu M. CMET-17. RENAL CELL CARCINOMA BRAIN METASTASES TREATED WITH STEREOTACTIC RADIATION THERAPY AND NIVOLUMAB DOES NOT ALTER LESIONAL OR CLINICAL OUTCOMES. Neuro-Oncology 2019, 21: vi54-vi55. PMCID: PMC6847278, DOI: 10.1093/neuonc/noz175.218.Peer-Reviewed Original ResearchStereotactic radiotherapyMedian timeRenal cell carcinoma brain metastasesDistant brain failureStage IV RCCMedian overall survivalOptimal treatment sequenceCox regression modelStereotactic radiation therapyWarrants further investigationDistant brainEligible lesionsNivolumab administrationBrain metastasesConsecutive patientsOverall survivalClinical outcomesBrain failureKaplan-MeierRetrospective databaseHemorrhagic lesionsNivolumabRadiation therapyPatient basisPatientsOA15 Clinical Outcomes of Breast Leptomeningeal Disease Treated with Intrathecal Trastuzumab, Intrathecal Chemotherapy, or Whole Brain Radiation Therapy
Figura N, Mohammadi H, Rizk V, Evernden B, Mokhtari S, Yu H, Robinson T, Etame A, Tran N, Diaz R, Soliman H, Han H, Sahebjam S, Forsyth P, Ahmed K. OA15 Clinical Outcomes of Breast Leptomeningeal Disease Treated with Intrathecal Trastuzumab, Intrathecal Chemotherapy, or Whole Brain Radiation Therapy. International Journal Of Radiation Oncology • Biology • Physics 2019, 103: e7. DOI: 10.1016/s0360-3016(19)30416-x.Peer-Reviewed Original Research
2017
Correlation of Molecular Features With Clinical Outcomes in Glioblastoma Treated with Chemoradiation
Liveringhouse C, Grass G, Ahmed K, Naghavi A, Macaulay R, Etame A, Tran N, Forsyth P, Sahebjam S, Johnstone P, Robinson T, Yu M. Correlation of Molecular Features With Clinical Outcomes in Glioblastoma Treated with Chemoradiation. International Journal Of Radiation Oncology • Biology • Physics 2017, 99: e605-e606. DOI: 10.1016/j.ijrobp.2017.06.2058.Peer-Reviewed Original Research